Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 2/20 | 0.61 |
| ▸ | COPS5 | Q92905 | 2/20 | 0.61 |
| ▸ | CCR1 | P32246 | 3/20 | 0.59 |
| ▸ | CCR8 | P51685 | 3/20 | 0.59 |
| ▸ | CCR5 | P51681 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035878 | 0.84 | HTT (0.61) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL2607397 | 0.81 | PSMD14 (0.68) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL13484093 | 0.78 | CCR1 (0.68) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL1195473 | 0.76 | KDM4E (0.46) | PSMD14COPS5L3MBTL1HTTSLC6A2 | |
| SCHEMBL3271557 | 0.76 | PSMD14 (0.61) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL1187430 | 0.76 | HTT (0.72) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL3630037 | 0.76 | KDM4E (0.53) | CCR1CCR8L3MBTL1HTTSLC6A2 | |
| SCHEMBL4013888 | 0.76 | HTR1A (0.56) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL21033695 | 0.76 | PSMD14 (0.61) | PSMD14COPS5CCR1CCR8CCR5 | |
| SCHEMBL440408 | 0.76 | NR4A2 (0.61) | HTTALDH1A1HSP90AA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-09-22 | — | — | US | disclosed |
| EP-4010328-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-06-15 | — | — | EP | disclosed |
| CN-114269730-A | 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists | 多曼治疗学公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-108771681-B | Co-crystals of compounds and deuterated derivatives thereof as DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2021-06-15 | — | — | CN | disclosed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2021023813-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-02-11 | — | — | WO | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| CN-106977495-B | DNA-PK inhibitors | 沃泰克斯药物股份有限公司 | 2020-08-04 | — | — | CN | disclosed |
| WO-2009062285-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.I.C. | 2009-04-09 | — | — | US | disclosed |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-29 | — | — | US | disclosed |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
| CN-101120011-A | Macrolides | PFIZER PROD INC (US) | 2008-02-06 | — | — | CN | disclosed |
| EP-1836211-A1 | MACROLIDES | Pfizer Products Incorporated (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006067589-A1 | MACROLIDES | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | PSMD14 4609/4885COPS5 1854/4885CCR1 2597/4885 |
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | PSMD14 2531/4885COPS5 2054/4885CCR1 1678/4885 |
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PSMD14 4232/4885COPS5 4316/4885CCR1 2529/4885 |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | PSMD14 4609/4885COPS5 1854/4885CCR1 2597/4885 |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | PSMD14 4609/4885COPS5 1854/4885CCR1 2597/4885 |
| US-11021465-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PSMD14 4232/4885COPS5 4316/4885CCR1 2529/4885 |
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | NPFFR2, NPFFR1, OPRL1 | PSMD14 2624/4885COPS5 2053/4885CCR1 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.